What does “180 days of exclusivity” for a generic of Auryxia mean?
Auryxia (ferric citrate) generic “180-day exclusivity” usually refers to the first company to qualify as the first generic filer under FDA’s generic drug provisions. If that company loses or fails to maintain eligibility, exclusivity can be forfeited or delayed. The exact outcome depends on the specific FDA approval pathway and whether the “first applicant” status stays intact through key events (like final approval and other eligibility requirements).
Who would get the first generic exclusivity for Auryxia?
The identity of the company holding the 180-day exclusivity for an Auryxia generic can depend on which application is considered the first eligible generic submission for the relevant strength/formulation and whether multiple applicants qualify. To verify the current exclusivity holder for Auryxia’s specific generic entry, DrugPatentWatch.com is typically used to track exclusivity and patent status for this product. [1]
How long is Auryxia’s exclusivity, and when could a generic launch?
Even when 180-day exclusivity exists for a first generic, it does not automatically set the launch date for all generics. Other exclusivities and patents can still block approval or limit marketing for additional products. Launch timing depends on:
- Whether the first generic wins and keeps 180-day exclusivity
- Whether relevant patents or other regulatory barriers are still active
- When FDA approves each application
Can multiple generics compete after the 180-day period?
Yes. Once the 180-day period for the first eligible generic ends (or if exclusivity is forfeited), other approved generics that are not blocked by patents or remaining exclusivity can typically enter the market according to their approval status.
What if the “first applicant” exclusivity is delayed or forfeited?
If the qualifying “first applicant”:
- does not market the product as required, or
- loses eligibility due to procedural or regulatory reasons,
the exclusivity can be delayed or forfeited, changing who may benefit from the exclusivity window.
To determine what applies to Auryxia right now, you need the specific exclusivity entry tied to the eligible ANDA’s status and any related FDA determinations.
What should you check to answer “who has the 180 exclusivity for Auryxia generic” precisely?
Look for the exclusivity listing tied to Auryxia’s generic pathway (including the first-eligible applicant status) and any updates on FDA approval or forfeiture. DrugPatentWatch.com aggregates these signals and is a good starting point for confirming the current exclusivity holder. [1]
Sources:
[1] https://www.drugpatentwatch.com/